Standard

Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia. / Fakhfouri, Gohar; Khlghatyan, Jivan; Sukhanov, Ilya; Gainetdinov, Raul R.; Beaulieu, Jean Martin.

Handbook of Behavioral Neuroscience. Elsevier, 2016. стр. 447-462 (Handbook of Behavioral Neuroscience; Том 23).

Результаты исследований: Публикации в книгах, отчётах, сборниках, трудах конференцийглава/разделРецензирование

Harvard

Fakhfouri, G, Khlghatyan, J, Sukhanov, I, Gainetdinov, RR & Beaulieu, JM 2016, Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia. в Handbook of Behavioral Neuroscience. Handbook of Behavioral Neuroscience, Том. 23, Elsevier, стр. 447-462. https://doi.org/10.1016/B978-0-12-800981-9.00026-2

APA

Fakhfouri, G., Khlghatyan, J., Sukhanov, I., Gainetdinov, R. R., & Beaulieu, J. M. (2016). Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia. в Handbook of Behavioral Neuroscience (стр. 447-462). (Handbook of Behavioral Neuroscience; Том 23). Elsevier. https://doi.org/10.1016/B978-0-12-800981-9.00026-2

Vancouver

Fakhfouri G, Khlghatyan J, Sukhanov I, Gainetdinov RR, Beaulieu JM. Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia. в Handbook of Behavioral Neuroscience. Elsevier. 2016. стр. 447-462. (Handbook of Behavioral Neuroscience). https://doi.org/10.1016/B978-0-12-800981-9.00026-2

Author

Fakhfouri, Gohar ; Khlghatyan, Jivan ; Sukhanov, Ilya ; Gainetdinov, Raul R. ; Beaulieu, Jean Martin. / Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia. Handbook of Behavioral Neuroscience. Elsevier, 2016. стр. 447-462 (Handbook of Behavioral Neuroscience).

BibTeX

@inbook{fd0ce995fdd34d60908fcf0f888980ac,
title = "Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia",
abstract = "Since the discovery of the mechanism of action of typical antipsychotics in 1975, the dopamine theory of schizophrenia remains one of the principal doctrines to explain the pathogenesis of schizophrenia. According to this theory, increased dopaminergic neurotransmission involving D2 receptors results in dysregulation of intracellular signaling mechanisms, leading to manifestations of schizophrenia. D2 receptors signal through G protein-dependent and G protein-independent pathways, the latter involving Akt/GSK3 has proved to play a major role to the schizopheric phenotypes. GSK3 is known to play central roles in the regulation of metabolism, synaptic plasticity, and neurodevelopment. Moreover, several prominent risk factors and contributors of the disease converge on these downstream effectors of D2 receptor signaling. Finally, the medications used clinically for the management of schizophrenia affect this signaling pathway. Here, we review the signaling systems altered in schizophrenia with a focus on GSK3 networks and discuss their involvement in the pathophysiology of the disease as well as their potential for the development of diagnostic and therapeutic tools.",
keywords = "Antipsychotics, D2 receptor, GSK3, Monoamine, Schizophrenia, Wnt",
author = "Gohar Fakhfouri and Jivan Khlghatyan and Ilya Sukhanov and Gainetdinov, {Raul R.} and Beaulieu, {Jean Martin}",
year = "2016",
month = jan,
day = "1",
doi = "10.1016/B978-0-12-800981-9.00026-2",
language = "English",
series = "Handbook of Behavioral Neuroscience",
publisher = "Elsevier",
pages = "447--462",
booktitle = "Handbook of Behavioral Neuroscience",
address = "Netherlands",

}

RIS

TY - CHAP

T1 - Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia

AU - Fakhfouri, Gohar

AU - Khlghatyan, Jivan

AU - Sukhanov, Ilya

AU - Gainetdinov, Raul R.

AU - Beaulieu, Jean Martin

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Since the discovery of the mechanism of action of typical antipsychotics in 1975, the dopamine theory of schizophrenia remains one of the principal doctrines to explain the pathogenesis of schizophrenia. According to this theory, increased dopaminergic neurotransmission involving D2 receptors results in dysregulation of intracellular signaling mechanisms, leading to manifestations of schizophrenia. D2 receptors signal through G protein-dependent and G protein-independent pathways, the latter involving Akt/GSK3 has proved to play a major role to the schizopheric phenotypes. GSK3 is known to play central roles in the regulation of metabolism, synaptic plasticity, and neurodevelopment. Moreover, several prominent risk factors and contributors of the disease converge on these downstream effectors of D2 receptor signaling. Finally, the medications used clinically for the management of schizophrenia affect this signaling pathway. Here, we review the signaling systems altered in schizophrenia with a focus on GSK3 networks and discuss their involvement in the pathophysiology of the disease as well as their potential for the development of diagnostic and therapeutic tools.

AB - Since the discovery of the mechanism of action of typical antipsychotics in 1975, the dopamine theory of schizophrenia remains one of the principal doctrines to explain the pathogenesis of schizophrenia. According to this theory, increased dopaminergic neurotransmission involving D2 receptors results in dysregulation of intracellular signaling mechanisms, leading to manifestations of schizophrenia. D2 receptors signal through G protein-dependent and G protein-independent pathways, the latter involving Akt/GSK3 has proved to play a major role to the schizopheric phenotypes. GSK3 is known to play central roles in the regulation of metabolism, synaptic plasticity, and neurodevelopment. Moreover, several prominent risk factors and contributors of the disease converge on these downstream effectors of D2 receptor signaling. Finally, the medications used clinically for the management of schizophrenia affect this signaling pathway. Here, we review the signaling systems altered in schizophrenia with a focus on GSK3 networks and discuss their involvement in the pathophysiology of the disease as well as their potential for the development of diagnostic and therapeutic tools.

KW - Antipsychotics

KW - D2 receptor

KW - GSK3

KW - Monoamine

KW - Schizophrenia

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=84999018496&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800981-9.00026-2

DO - 10.1016/B978-0-12-800981-9.00026-2

M3 - Chapter

AN - SCOPUS:84999018496

T3 - Handbook of Behavioral Neuroscience

SP - 447

EP - 462

BT - Handbook of Behavioral Neuroscience

PB - Elsevier

ER -

ID: 36300074